- Home
- SES vs LYEL Comparison
SES vs LYEL Comparison
Compare SES & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SES | LYEL |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 836.0M | 681.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SES | LYEL |
|---|---|---|
| Price | $2.02 | $37.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $4.00 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 6.2M | 85.8K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,478,000.00 | $41,000.00 |
| Revenue This Year | $1,007.16 | N/A |
| Revenue Next Year | $131.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.38 | $7.65 |
| 52 Week High | $3.73 | $45.00 |
Technical Indicators
Market Signals| Indicator | SES | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 49.23 | 79.25 |
| Support Level | $1.89 | $32.01 |
| Resistance Level | $2.07 | $45.00 |
| Average True Range (ATR) | 0.17 | 3.34 |
| MACD | 0.00 | 0.53 |
| Stochastic Oscillator | 36.61 | 67.75 |
Price Performance
Historical ComparisonAbout SES SES AI Corporation
SES AI Corp is a developer and manufacturer of high-performance, AI-enhanced Lithium-Metal (Li-Metal) and Lithium-ion (Li-ion) rechargeable battery technologies for electric vehicles (EVs), Urban Air Mobility (UAM), drones, robotics, Battery Energy Storage Systems (BESS) and other applications. It includes Software and Hardware products that are EV, UAM, Drone, Molecular Universe, and Avatar.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.